335 related articles for article (PubMed ID: 32350552)
1. Noncoding RNAs in Duchenne and Becker muscular dystrophies: role in pathogenesis and future prognostic and therapeutic perspectives.
Brusa R; Magri F; Bresolin N; Comi GP; Corti S
Cell Mol Life Sci; 2020 Nov; 77(21):4299-4313. PubMed ID: 32350552
[TBL] [Abstract][Full Text] [Related]
2. The X-linked Becker muscular dystrophy (bmx) mouse models Becker muscular dystrophy via deletion of murine dystrophin exons 45-47.
Heier CR; McCormack NM; Tully CB; Novak JS; Newell-Stamper BL; Russell AJ; Fiorillo AA
J Cachexia Sarcopenia Muscle; 2023 Apr; 14(2):940-954. PubMed ID: 36628607
[TBL] [Abstract][Full Text] [Related]
3. Noncoding RNAs and Duchenne muscular dystrophy.
Perry MM; Muntoni F
Epigenomics; 2016 Nov; 8(11):1527-1537. PubMed ID: 27603567
[TBL] [Abstract][Full Text] [Related]
4. Causes of clinical variability in Duchenne and Becker muscular dystrophies and implications for exon skipping therapies.
Hoffman EP
Acta Myol; 2020 Dec; 39(4):179-186. PubMed ID: 33458572
[TBL] [Abstract][Full Text] [Related]
5. Antisense Oligonucleotide Treatment in a Humanized Mouse Model of Duchenne Muscular Dystrophy and Highly Sensitive Detection of Dystrophin Using Western Blotting.
Maruyama R; Yokota T
Methods Mol Biol; 2021; 2224():203-214. PubMed ID: 33606217
[TBL] [Abstract][Full Text] [Related]
6. Biomarker Potential of Extracellular miRNAs in Duchenne Muscular Dystrophy.
Coenen-Stass AML; Wood MJA; Roberts TC
Trends Mol Med; 2017 Nov; 23(11):989-1001. PubMed ID: 28988850
[TBL] [Abstract][Full Text] [Related]
7. Duchenne and Becker muscular dystrophy: from gene diagnosis to molecular therapy.
Matsuo M
IUBMB Life; 2002 Mar; 53(3):147-52. PubMed ID: 12102170
[TBL] [Abstract][Full Text] [Related]
8. MicroRNAs as serum biomarkers in Becker muscular dystrophy.
Gagliardi D; Rizzuti M; Brusa R; Ripolone M; Zanotti S; Minuti E; Parente V; Dioni L; Cazzaniga S; Bettica P; Bresolin N; Comi GP; Corti S; Magri F; Velardo D
J Cell Mol Med; 2022 Sep; 26(17):4678-4685. PubMed ID: 35880500
[TBL] [Abstract][Full Text] [Related]
9. Dystrophin and the two related genetic diseases, Duchenne and Becker muscular dystrophies.
Le Rumeur E
Bosn J Basic Med Sci; 2015 Jul; 15(3):14-20. PubMed ID: 26295289
[TBL] [Abstract][Full Text] [Related]
10. Biochemical characterization of patients with in-frame or out-of-frame DMD deletions pertinent to exon 44 or 45 skipping.
Anthony K; Arechavala-Gomeza V; Ricotti V; Torelli S; Feng L; Janghra N; Tasca G; Guglieri M; Barresi R; Armaroli A; Ferlini A; Bushby K; Straub V; Ricci E; Sewry C; Morgan J; Muntoni F
JAMA Neurol; 2014 Jan; 71(1):32-40. PubMed ID: 24217213
[TBL] [Abstract][Full Text] [Related]
11. In Vitro Multiexon Skipping by Antisense PMOs in Dystrophic Dog and Exon 7-Deleted DMD Patient.
Nakamura A; Aoki Y; Tsoumpra M; Yokota T; Takeda S
Methods Mol Biol; 2018; 1828():151-163. PubMed ID: 30171540
[TBL] [Abstract][Full Text] [Related]
12. Duchenne and Becker muscular dystrophies.
Flanigan KM
Neurol Clin; 2014 Aug; 32(3):671-88, viii. PubMed ID: 25037084
[TBL] [Abstract][Full Text] [Related]
13. Duchenne and Becker Muscular Dystrophies: A Review of Animal Models, Clinical End Points, and Biomarker Quantification.
Wilson K; Faelan C; Patterson-Kane JC; Rudmann DG; Moore SA; Frank D; Charleston J; Tinsley J; Young GD; Milici AJ
Toxicol Pathol; 2017 Oct; 45(7):961-976. PubMed ID: 28974147
[TBL] [Abstract][Full Text] [Related]
14. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.
Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T
Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998
[TBL] [Abstract][Full Text] [Related]
15. Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy.
Miyatake S; Mizobe Y; Takizawa H; Hara Y; Yokota T; Takeda S; Aoki Y
Methods Mol Biol; 2018; 1687():123-141. PubMed ID: 29067660
[TBL] [Abstract][Full Text] [Related]
16. MicroRNAs in Dystrophinopathy.
Lee A; Moon J; Yu J; Kho C
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887128
[TBL] [Abstract][Full Text] [Related]
17. The Role of MicroRNA in the Pathogenesis of Duchenne Muscular Dystrophy.
Kiełbowski K; Bakinowska E; Procyk G; Ziętara M; Pawlik A
Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892293
[TBL] [Abstract][Full Text] [Related]
18. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing.
Hanson B; Wood MJA; Roberts TC
RNA Biol; 2021 Jul; 18(7):1048-1062. PubMed ID: 33472516
[TBL] [Abstract][Full Text] [Related]
19. Utrophin modulator drugs as potential therapies for Duchenne and Becker muscular dystrophies.
Soblechero-Martín P; López-Martínez A; de la Puente-Ovejero L; Vallejo-Illarramendi A; Arechavala-Gomeza V
Neuropathol Appl Neurobiol; 2021 Oct; 47(6):711-723. PubMed ID: 33999469
[TBL] [Abstract][Full Text] [Related]
20. Dystromirs as serum biomarkers for monitoring the disease severity in Duchenne muscular Dystrophy.
Zaharieva IT; Calissano M; Scoto M; Preston M; Cirak S; Feng L; Collins J; Kole R; Guglieri M; Straub V; Bushby K; Ferlini A; Morgan JE; Muntoni F
PLoS One; 2013; 8(11):e80263. PubMed ID: 24282529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
